PMID- 30810253
OWN - NLM
STAT- MEDLINE
DCOM- 20190805
LR  - 20190805
IS  - 1742-1241 (Electronic)
IS  - 1368-5031 (Linking)
VI  - 73
IP  - 5
DP  - 2019 May
TI  - Solithromycin monotherapy for treatment of community-acquired bacterial 
      pneumonia: A meta-analysis of randomised controlled trials.
PG  - e13333
LID - 10.1111/ijcp.13333 [doi]
AB  - OBJECTIVES: Solithromycin is a new monotherapy option for community-acquired 
      bacterial pneumonia (CABP) patients. However, the efficacy and safety of 
      solithromycin monotherapy for the treatment of CABP remains controversial. The 
      aim of this meta-analysis was to evaluate the role that solithromycin played in 
      the treatment of CABP. METHODS: We systematically retrieved randomised controlled 
      trials (RCTs) compared solithromycin with other antibiotics in the treatment of 
      CABP, which were published on PubMed, ScienceDirect, Cochrane libary and the 
      Clinical Trials.gov before July 2018. Ultimately, a meta-analysis of all RCTs 
      eligible for inclusion criteria was performed. RESULTS: Three RCTs, comprising 
      1855 patients, were included in the meta-analysis. There were no statistically 
      significant differences between patients given solithromycin and those given 
      other antibiotics with regard to early clinical response (ECR) [1855 patients, 
      odds ratio (OR) = 1.00, 95% confidence interval (CI) 0.80 to 1.24, P = 0.99] and 
      clinical success rates at short-term follow-up (SFU) (1855 patients, OR = 0.78, 
      95% CI 0.60 to 1.01, P = 0.06) in the intention-to-treat (ITT) population, as 
      were the ECR (787 patients, OR = 0.90, 95% CI 0.64 to 1.27, P = 0.55) and 
      clinical success rates at SFU (358 patients, OR = 0.73, 95% CI 0.41 to 1.31, 
      P = 0.30) in microbiological intention-to-treat population (mITT). Similarly, 
      with regard to the occurrence of treatment-emergent adverse events (TEAEs), 
      drug-related adverse events (AEs), serious AEs, serious drug-related AEs and 
      mortality, no statistically significant difference between patients given 
      solithromycin and those given other antibiotics was observed. CONCLUSION: In the 
      treatment of CABP, solithromycin monotherapy is an effective and safe antibiotic 
      regimen. Other advantages (ie anti-inflammatory effect, potent activity 
      against expected pathogens of CABP and convenient clinical use) of solithromycin 
      may make it a more fascinating option compared with the currently used regimens.
CI  - (c) 2019 John Wiley & Sons Ltd.
FAU - Wen, Junlin
AU  - Wen J
AUID- ORCID: 0000-0002-6577-2779
AD  - Department of Pain Management, The First Affliated Hospital, Jinan University, 
      Guangzhou, China.
FAU - Chen, Feng
AU  - Chen F
AD  - Department of Pharmacy, Yuebei People's Hospital, Shaoguan, China.
FAU - Zhao, Mengxin
AU  - Zhao M
AD  - Department of Pain Management, The First Affliated Hospital, Jinan University, 
      Guangzhou, China.
FAU - Wang, Xiaoping
AU  - Wang X
AD  - Department of Pain Management, The First Affliated Hospital, Jinan University, 
      Guangzhou, China.
LA  - eng
GR  - Grant 2015108/The Fundamental Research Funds for the First Clinical Medicine 
      College of Jinan University/
GR  - 81572184/National Natural Science Foundation of China/
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20190314
PL  - India
TA  - Int J Clin Pract
JT  - International journal of clinical practice
JID - 9712381
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Macrolides)
RN  - 0 (Triazoles)
RN  - 9U1ETH79CK (solithromycin)
MH  - Anti-Bacterial Agents/*administration & dosage/adverse effects
MH  - Community-Acquired Infections/*drug therapy
MH  - Drug Administration Schedule
MH  - Female
MH  - Humans
MH  - Macrolides/*administration & dosage/adverse effects
MH  - Male
MH  - Middle Aged
MH  - Multicenter Studies as Topic
MH  - Pneumonia, Bacterial/*drug therapy
MH  - Randomized Controlled Trials as Topic
MH  - Triazoles/*administration & dosage/adverse effects
EDAT- 2019/02/28 06:00
MHDA- 2019/08/06 06:00
CRDT- 2019/02/28 06:00
PHST- 2018/08/14 00:00 [received]
PHST- 2019/01/09 00:00 [revised]
PHST- 2019/02/24 00:00 [accepted]
PHST- 2019/02/28 06:00 [pubmed]
PHST- 2019/08/06 06:00 [medline]
PHST- 2019/02/28 06:00 [entrez]
AID - 10.1111/ijcp.13333 [doi]
PST - ppublish
SO  - Int J Clin Pract. 2019 May;73(5):e13333. doi: 10.1111/ijcp.13333. Epub 2019 Mar 
      14.